MET and non-small cell lung carcinoma: According to the recent updated guidelines, molecular testing in NSCLC includes three classes of targets: the “must-test” biomarkers with approved targeted therapies (i.e., epidermal growth factor receptor (EGFR)); “should-test” biomarkers (i.e., MET proto-oncogene, receptor tyrosine kinase (MET)), crucial to eventually direct patients to ongoing clinical trials and “investigational” biomarkers, without a clear clinical value at the moment.